Insiders Trades
Hercules Capital, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 30 Mar 2026.
Hercules Capital, Inc.: what insiders have been doing
This page follows insider dealings at Hercules Capital, Inc. as filed with SEC (Form 4), a company from the Finance & Banking sector. The last twelve months, up to 18 October 2026, brought 66 filings signed by 12 insiders.
Only purchases show up on the open market, 24 purchases in all worth €2.5M, filed by 11 insiders. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Biggest ticket of the year: €384k, bought by Bluestein Scott and made public on 24 February 2026. The buyers include 9 senior executives, 1 finance chief and 1 chief executive.
In all, 23 purchases were made within 30 days of a purchase by another insider of the company. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The most recent open-market purchase was published on 30 March 2026, 202 days ago. Typically, a trade is published a median of 4 days after it takes place. Section 16 rules allow two business days to file each Form 4.
For context, the typical company on the same exchange (median of 5,458 companies) published 22 filings over the same period, against 66 filings here. Looking back to 2016, when coverage begins, insiders filed 41 purchases and 5 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported net income of 339.7 m USD.
Other companies in the same sector with recent insider buying flagged by our signals: First Guaranty Bancshares, Inc. and BCB Bancorp Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
332
Thresholds
n/a
Buy Volume
€3M
41 ops. · all time
Sell Volume
€4M
5 ops. · all time
Who traded when
BuySaleThomas J. Fallon5 buys
Gayle A. Crowell4 buys
Nikos Theodosopoulos4 buys
Robert P. Badavas4 buys
Wade Loo3 buys
Christian Follmann1 buy1 sale
+5 other insiders
Since the insiders bought
- -15.3%Entry 0.47 · Close at T+90 0.40
- -15.3%Entry 0.47 · Close at T+90 0.40
- -15.3%Entry 0.47 · Close at T+90 0.40
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
· cache
Last declaration on 13 October 2026
Declarations332 total
3,011 shares@ US$16.51Common StockSEC:0001768773-26-000011:0
1,018 shares@ US$16.51Common StockSEC:0001902313-26-000007:0
3,458 shares@ US$16.51Common StockSEC:0001768773-26-000011:1
9,741 shares@ US$16.51Common StockSEC:0001505910-26-000009:0
10,652 shares@ US$16.51Common StockSEC:0001505910-26-000009:1
956 shares@ US$16.51Common StockSEC:0001902313-26-000007:1
1,365 shares@ US$16.51Common StockSEC:0001907321-26-000008:0
1,433 shares@ US$16.51Common StockSEC:0001907321-26-000008:1
3,483 shares@ US$17.760.018% mcap100.0% of flowCommon StockSEC:0002092805-26-000002:0
5 shares@ US$17.610.0000% mcap0.0% of flowCommon StockSEC:0001768773-26-000010:0
9,741 shares@ US$15.690.045% mcap0.2% of flowCommon StockSEC:0001505910-26-000008:0
10,652 shares@ US$15.690.049% mcap0.3% of flowCommon StockSEC:0001505910-26-000008:1
956 shares@ US$15.690.0044% mcap0.7% of flowCommon StockSEC:0001902313-26-000006:0
1,433 shares@ US$15.690.0066% mcap0.9% of flowCommon StockSEC:0001907321-26-000007:0
3,458 shares@ US$15.690.016% mcap0.6% of flowCommon StockSEC:0001768773-26-000009:1
1,018 shares@ US$15.690.0047% mcap0.8% of flowCommon StockSEC:0001902313-26-000006:1
1,365 shares@ US$15.690.0063% mcap0.9% of flowCommon StockSEC:0001907321-26-000007:1
3,011 shares@ US$15.690.014% mcap0.5% of flowCommon StockSEC:0001768773-26-000009:0
3,873 sharesCommon StockSEC:0001207407-26-000009:0
3,873 sharesCommon StockSEC:0001207407-26-000010:0
3,873 sharesCommon StockSEC:0001207407-26-000011:0
3,873 sharesCommon StockSEC:0001207407-26-000008:0
10,652 shares@ US$14.740.2% of flowCommon StockSEC:0001505910-26-000005:0
9,741 shares@ US$14.740.2% of flowCommon StockSEC:0001505910-26-000005:1
956 shares@ US$14.740.7% of flowCommon StockSEC:0001902313-26-000004:0
25 of 332 declarations
About Hercules Capital, Inc.
Hercules Capital, Inc. (NYSE: HTGC) is a U.S.-based specialty finance company headquartered in San Mateo, California, United States. For French-speaking investors, it is best understood as a leading business development company (BDC) focused on venture lending: providing debt capital to innovative, venture capital-backed companies. Hercules describes itself as the largest and leading specialty finance company concentrated on this niche, and as a lender of choice for innovative entrepreneurs and their venture capital sponsors. ([htgc.com](https://www.htgc.com/about/?utm_source=openai))
The company’s core activity is senior secured lending and growth financing for companies in high-innovation sectors, especially technology and life sciences. Its financing solutions typically support growth capital needs, expansion, product development, working capital, and other strategic corporate initiatives. In practice, Hercules offers an alternative to conventional commercial bank lending, with a more tailored and flexible structure designed for companies that may be too early, too specialized, or too growth-oriented for traditional lenders. ([htgc.com](https://www.htgc.com/about/?utm_source=openai))
Read moreShow less
Hercules Capital’s business model is closely tied to the venture ecosystem. It has built its franchise by serving venture-backed businesses at different stages, from earlier growth companies to more established issuers that still need non-dilutive capital. The firm’s headquarters are in San Mateo, California, and its operating footprint is primarily U.S.-centric, although its client base can include companies with broader domestic or international ambitions depending on their financing needs. ([htgc.com](https://www.htgc.com/contact-us/?utm_source=openai))
From a competitive standpoint, Hercules benefits from deep sector specialization, strong relationships with venture capital firms, and a long-standing reputation in a relatively niche corner of the credit market. That specialization matters: technology and life sciences borrowers often require financing that is more flexible than bank debt but less dilutive than equity. Hercules is positioned to fill that gap, which supports its market relevance and gives it access to a differentiated deal flow versus more generalist lenders. ([htgc.com](https://www.htgc.com/about/?utm_source=openai))
Recent developments have remained supportive of the investment case. In May 2025 and again in May 2026, Hercules reported quarterly results highlighting strong originations and liquidity levels above $1.0 billion at quarter-end. The company also disclosed record new debt and equity commitments in Q1 2026, indicating that demand for its capital remains robust. For investors following SEC Form 4 insider transactions, HTGC is therefore a name to watch both for credit performance and for management confidence signals through insider activity. ([businesswire.com](https://www.businesswire.com/news/home/20250501258025/en/Hercules-Capital-Reports-First-Quarter-2025-Financial-Results?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
